<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04211571</url>
  </required_header>
  <id_info>
    <org_study_id>KNU-Theranova-01</org_study_id>
    <nct_id>NCT04211571</nct_id>
  </id_info>
  <brief_title>Theranova Versus High-flux Dialyzer on Preservation of Residual Renal Function</brief_title>
  <official_title>Randomized Controlled Trial of Theranova Versus High-flux Dialyzer on Preservation of Residual Renal Function in Incident Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyungpook National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kyungpook National University Chilgok Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yeungnam University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ewha Womans University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyungpook National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Theranova is a novel medium cut-off dialyzer and has better performance for removal of middle
      molecules compared to conventional hemodialysis. The study investigates the effect of
      Theranova dialzyer on preserving residual renal function in the incident hemodialysis
      pateitns compared to high-flux dialzyer. The primary endpoint is change of glomerular
      filtration rate, calculated using creatinine and urea clearance. The secondary endpoints are
      glomerular filtration rate, daily urine volume, serum middle molecule concentrations,
      hospitalization, mortality, and patient reporeted outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of glomerular filtration rate</measure>
    <time_frame>Between baseline and 12 months</time_frame>
    <description>Glomerular filtration rate is calculated as the mean of creatinine and urea clearance adjusted for body surface area. The outcome refers to the mean difference of glomerular filtration rate between baseline and after 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of glomerular filtration rate</measure>
    <time_frame>0, 12 months</time_frame>
    <description>Calculated as the mean of creatinine and urea clearance adjusted for body surface area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of daily urine volume</measure>
    <time_frame>0, 12 months</time_frame>
    <description>Total urine output for 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of inflammatory marker levels</measure>
    <time_frame>0, 12 months</time_frame>
    <description>hs-CRP, IL-6, TNF-alpha etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentration of Beta 2-microglobulin</measure>
    <time_frame>0, 12 months</time_frame>
    <description>Pre-dialysis concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentration of Kappa and lambda free light chains</measure>
    <time_frame>0, 12 months</time_frame>
    <description>Pre-dialysis concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>Through 12-month study duration</time_frame>
    <description>Frequency, cause, length of hospital stay, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Through 12-month study duration</time_frame>
    <description>Deaths number and causes of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcome</measure>
    <time_frame>0, 12 months</time_frame>
    <description>Using Kidney Disease Quality of Life Questionnaire-36™ (KDQOL-36™; score ranges from 0 to 100 - higher scores represent better quality of life)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>MCO group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemodialysis using Theranova 400 dialyzer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-flux group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hemodialysis using high-flux dialyzer (Fx CorDiax 60 and 80; Fresenius Medical Care)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Theranova 400 dialyzer</intervention_name>
    <description>Hemodialysis using Theranova 400 dialyzer</description>
    <arm_group_label>MCO group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High-flux dialyzer</intervention_name>
    <description>Hemodialysis using high-flux dialyzer</description>
    <arm_group_label>High-flux group</arm_group_label>
    <other_name>Fx CorDiax 60 and 80 dialyzer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Incident end-stage renal disease ESRD patient receiving hemodialysis for less than 1
             month

          -  18 years old and older

          -  Vascular access by arteriovenous fistula/graft

          -  Creatinine clearance of more than 2 ml/min

          -  Agreement to participate in the clinical study

        Exclusion Criteria:

          -  Dialysis through permanent catheter

          -  Plan for kidney transplantation within 6 months

          -  Severe volume overloading state

          -  Any hematologic malignancy or monoclonal gammopathy

          -  Any malignancy

          -  Active infectious disease

          -  HIV infection

          -  Patient enrolled to another study within 3 month from starting the present study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jeong-Hoon Lim, MD, PhD</last_name>
    <phone>+82-53-200-5559</phone>
    <email>hunph84@naver.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jang-Hee Cho, MD, PhD</last_name>
    <phone>+82-53-200-5550</phone>
    <email>jh-cho@knu.ac.kr</email>
  </overall_contact_backup>
  <reference>
    <citation>Kirsch AH, Lyko R, Nilsson LG, Beck W, Amdahl M, Lechner P, Schneider A, Wanner C, Rosenkranz AR, Krieter DH. Performance of hemodialysis with novel medium cut-off dialyzers. Nephrol Dial Transplant. 2017 Jan 1;32(1):165-172. doi: 10.1093/ndt/gfw310.</citation>
    <PMID>27587605</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 21, 2019</study_first_submitted>
  <study_first_submitted_qc>December 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2019</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyungpook National University Hospital</investigator_affiliation>
    <investigator_full_name>Yong-Lim Kim</investigator_full_name>
    <investigator_title>M.D., Ph.D.</investigator_title>
  </responsible_party>
  <keyword>End-stage renal disease</keyword>
  <keyword>Medium cut-off dialyzer</keyword>
  <keyword>High-flux dialyzer</keyword>
  <keyword>Residual renal function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

